Ligia de Souza Fernandes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ligia de Souza Fernandes has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Alécia Junia Aparecida Santos
Laboratory of Pharmacology, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, Minas Gerais, Brazil
1 shared publicationElton Libério da Silva
Laboratory of Pharmacology, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, Minas Gerais, Brazil
1 shared publicationFlávia Do Carmo Horta Pinto
Natural Sciences Department, Federal University of São João Del-Rei, Campus Dom Bosco, São João Del-Rei, Minas Gerais, Brazil
1 shared publicationFranciele Natália Peixoto
Laboratory of Pharmacology, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, Minas Gerais, Brazil
1 shared publication- Gabriel Davi Marena
Laboratório de Fungos Dimórficos Patogênicos, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, Brazil
1 shared publication - Jonatas Lobato Duarte
School of Pharmaceutical Sciences, São Paulo State University “Julio de Mesquita Filho”—(UNESP), Araraquara 14800-903, SP, Brazil
1 shared publication
Latest Publications
- 1 April 2023
- Published by Taylor & Francis in Nanomedicine
- Vol. 18 (10) , 789-801
Design of Rapamycin and Resveratrol Coloaded Liposomal Formulation for Breast Cancer Therapy
Aims: The development of rapamycin (RAP) and resveratrol (RSV) coloaded liposomes (RAP-RSV-LIP) for breast cancer therapy. Materials & methods: Liposomes were prepared using a high-pressure homogen...
- 1 April 2023
- Published by Taylor & Francis in Nanomedicine
- Vol. 18 (10) , 789-801
Design of Rapamycin and Resveratrol Coloaded Liposomal Formulation for Breast Cancer Therapy
Aims: The development of rapamycin (RAP) and resveratrol (RSV) coloaded liposomes (RAP-RSV-LIP) for breast cancer therapy. Materials & methods: Liposomes were prepared using a high-pressure homogen...
Formulation, stability study and preclinical evaluation of a vaginal cream containing curcumin in a rat model of vulvovaginal candidiasis
Summary: Owing to the growing resistance among isolates of Candida species to usual antifungal agents and the well‐known therapeutic potential of curcumin, the purpose of this study was to develop and validate a vaginal formulation containing this substance and to evaluating its effectiveness in the treatment of experimental vulvovaginal candidiasis. Curcumin was incorporated in a vaginal cream in three concentrations (0.01%, 0.1% and 1.0%). The different concentrations of the cream and its controls were intravaginally administered in an immunosuppressed rat model to evaluate the efficacy in the treatment of experimental vulvovaginal candidiasis. Samples of the cream were also subjected to centrifugation and physical stability tests and an analytical method for quantification of curcumin was validated based on HPLC. The formulation was stable and the HPLC method could be considered suitable for the quantitative determination of curcumin in the cream. After 6 days of preclinical study, the number of infected animals was 1/6 in all groups treated with curcumin vaginal cream and the fungal burden showed a progressive reduction. Reduction in the inflammatory infiltrate was observed in the group treated with 1.0% cream. Vaginal cream containing curcumin could be considered a promising effective antifungal medicine in the treatment of vulvovaginal candidiasis.
Formulation, stability study and preclinical evaluation of a vaginal cream containing curcumin in a rat model of vulvovaginal candidiasis
Summary: Owing to the growing resistance among isolates of Candida species to usual antifungal agents and the well‐known therapeutic potential of curcumin, the purpose of this study was to develop and validate a vaginal formulation containing this substance and to evaluating its effectiveness in the treatment of experimental vulvovaginal candidiasis. Curcumin was incorporated in a vaginal cream in three concentrations (0.01%, 0.1% and 1.0%). The different concentrations of the cream and its controls were intravaginally administered in an immunosuppressed rat model to evaluate the efficacy in the treatment of experimental vulvovaginal candidiasis. Samples of the cream were also subjected to centrifugation and physical stability tests and an analytical method for quantification of curcumin was validated based on HPLC. The formulation was stable and the HPLC method could be considered suitable for the quantitative determination of curcumin in the cream. After 6 days of preclinical study, the number of infected animals was 1/6 in all groups treated with curcumin vaginal cream and the fungal burden showed a progressive reduction. Reduction in the inflammatory infiltrate was observed in the group treated with 1.0% cream. Vaginal cream containing curcumin could be considered a promising effective antifungal medicine in the treatment of vulvovaginal candidiasis.